1.Zhavoronkov, A., et al. (2022). Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nature Biotechnology, 40(3), 123–135. https://doi.org/10.1038/s41587-021-01013-32.Topol, E. (2023). AI in Clinical Medicine: A Practical Guide. Wiley-Blackwell.3.Mak, K.K., & Pichika, M.R. (2023). Artificial intelligence in drug development. Drug Discovery Today, 28(1), 103–115. https://doi.org/10.1016/j.drudis.2022.10.0174.FDA (2023). Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device Action Plan.5.EMA (2024). Reflection Paper on the Use of AI in the Medicinal Product Lifecycle. https://www.ema.europa.eu6.McKinsey & Company (2023). Pharma 4.0: How AI is Transforming Drug Development.7.Deloitte (2024). Global AI in Pharma Market Forecast 2025–2030.8.NeurIPS (2023). Federated Learning for Healthcare Data Privacy. https://proceedings.neurips.cc